Drugs in MeSH Category Purinergic P1 Receptor Antagonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	019212-002	Nov 7, 1984		DISCN	No	No
Hospira	AMINOPHYLLINE	aminophylline	INJECTABLE;INJECTION	087601-001	Jul 23, 1982		DISCN	No	No
Panray	AMINOPHYLLINE	aminophylline	TABLET;ORAL	084552-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Alembic	THEOPHYLLINE	theophylline	TABLET, EXTENDED RELEASE;ORAL	090430-001	Oct 27, 2010	AB	RX	No	No
Teva Pharms Inc	THEOPHYLLINE	theophylline	TABLET, EXTENDED RELEASE;ORAL	216961-001	Oct 12, 2022	AB	RX	No	No
Intl Medication	AMINOPHYLLINE	aminophylline	INJECTABLE;INJECTION	087868-001	Nov 10, 1983		DISCN	No	No
Glenmark Pharms Ltd	THEOPHYLLINE	theophylline	TABLET, EXTENDED RELEASE;ORAL	212184-001	Jun 3, 2021	AB	RX	No	No

Market Dynamics and Patent Landscape for Purinergic P1 Receptor Antagonists (NLM MeSH Class)

Last updated: May 30, 2026

Executive summary Purinergic P1 receptor antagonists sit at the intersection of adenosine-pathway modulation and oncology, inflammation, and CNS indications. The patent landscape is dominated by (1) chemical matter around adenosine receptor antagonists, (2) formulation and route-of-administration IP (oral solids, parenterals, long-acting injectables, transdermal where applicable), and (3) method-of-use claims that tie blockade of A1/A2A/A2B/A3 to specific diseases and biomarkers. Market dynamics are shaped by the adenosine axis’s centrality in immuno-oncology, but commercial uptake is constrained by efficacy durability, safety tradeoffs (cardiovascular and immunologic), and differentiation risk versus progressing adenosine pathway competitors (A2A agonists/antagonists, CD73, CD39, and downstream immunomodulators).

Because “Purinergic P1 Receptor Antagonists” is a MeSH class, the relevant patent scope spans multiple active ingredients and sub-classes. Without a drug-by-drug anchor (active ingredient or FDA product), it is not possible to produce a complete, accurate patent estate map, Orange Book status table, or litigation/Paragraph IV timeline for this entire MeSH class in a single response.